**Core Concept**
The development of drug resistance in Tuberculosis (TB) is a complex phenomenon involving genetic mutations and alterations in the TB bacterium, Mycobacterium tuberculosis (M. tuberculosis). This resistance compromises the effectiveness of antitubercular therapy, making treatment more challenging and increasing the risk of treatment failure.

**Why the Correct Answer is Right**
Drug resistance in TB primarily arises from mutations in the genes encoding enzymes involved in the bacterial cell wall synthesis and DNA replication. The most common mechanisms of drug resistance in TB include:
* Mutations in the rpoB gene encoding the beta-subunit of RNA polymerase, which confers resistance to rifampicin.
* Mutations in the katG gene encoding the catalase-peroxidase enzyme, which confers resistance to isoniazid.
* Mutations in the inhA gene encoding the enoyl-acyl carrier protein reductase enzyme, which confers resistance to isoniazid.
* Mutations in the gyrA and gyrB genes encoding the DNA gyrase enzymes, which confers resistance to fluoroquinolones.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not specified and cannot be evaluated for correctness.
* **Option B:** This option is not specified and cannot be evaluated for correctness.
* **Option C:** This option is not specified and cannot be evaluated for correctness.

**Clinical Pearl / High-Yield Fact**
The World Health Organization (WHO) recommends the use of molecular diagnostic tests, such as the Xpert MTB/RIF assay, to rapidly detect drug-resistant TB and guide treatment.

**Correct Answer: C. Mutations in the genes encoding enzymes involved in bacterial cell wall synthesis and DNA replication.**